Semaglutide (Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro, Zepbound) are incretin mimetics approved for managing type 2 diabetes and long-term weight loss. Semaglutide acts as a GLP-1 receptor agonist, mimicking the natural GLP-1 hormone to regulate blood sugar and appetite. In contrast, Tirzepatide is a dual agonist that targets both GIP and GLP-1 receptors, enhancing the effects of these incretin hormones. Both medications are intended to be used alongside lifestyle changes, including a healthy diet and regular exercise.